ALM-003, a novel digital therapeutic (DTx), significantly reduced heavy drinking days (HDDs) compared to control in alcohol-dependent patients with high or very high drinking risk.
The intervention integrates daily self-monitoring, personalized feedback, psychoeducational modules, and automated physician support, enhancing psychosocial treatments.
Safety outcomes showed no adverse events attributable to app use, supporting the integration of DTx into clinical care without increased risk.
This landmark multicenter RCT substantiates digital therapeutics as an effective adjunct for alcohol dependence management.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
